热门资讯> 正文
Altimune直接发行价为7500万美元
2026-01-28 12:39
- Altimmune (ALT) entered into a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17.05M shares pursuant to a registered direct offering.
- The offering is expected to result in gross proceeds of ~$75M.
- All the shares and pre-funded warrants in the offering are being offered by Altimmune.
- The offering is expected to close on or about January 29, 2026.
- The net proceeds will be used to fund preparation for its upcoming Phase 3 trial in metabolic dysfunction-associated steatohepatitis as well as for working capital and general corporate purposes.
- The stock price traded 3% higher on Tuesday during after-market hours of trading.
More on Altimmune
- Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen
- Altimmune: Positives And Negatives Of The IMPACT Data And Recent Updates
- Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH - Slideshow
- Altimmune gains on FDA breakthrough designation for MASH therapy
- Altimmune posts mid-stage trial data showing antifibrotic activity of lead asset in MASH
推荐文章
一周IPO | 新消费IPO再受热捧！鸣鸣很忙首日涨近70%；大族数控、爱芯元智等五只新股正在招股中
打爆所有空头？Sandisk交出的“炸裂财报”再度引爆存储行情！周期或许远未见顶？
财报前瞻 | 4万亿美元市值迎大考！谷歌Q4财报能否为其“AI全栈”野心正名？
新股申购 | 两只新股今起招股！澜起科技一手入场费10796.80港元；爱芯元智一手入场费2848.44港元
华盛早报 | 特朗普今晚公布美联储新主席人选！沃什概率飙升至近8成；金银价格一度闪崩又回弹
美股机会日报 | Meta业绩亮眼盘前大涨9%！英伟达、微软等巨头被曝将向OpenAI投资600亿美元
港股突破28000点，接下来该如何布局？这三大方向尤获机构、北水青睐（附股）
微软Q2业绩会实录：大部分投入资本周期已通过合同锁定
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
